Clinical trials: Transarterial Chemoembolization
Hepatocellular Carcinoma (HCC)
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic…
- Trial name
- TACE HCC (NCT06990620)
- Testing
- TACE+AK112
- Volunteers
- 56 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Hepatocellular carcinoma (HCC) is the fourth most common cancer in China, with a crude incidence rate of 26.67 per 100,000 population. Moreover, 357,800 new liver cancer cases are predicted to be diagnosed in China in 2020.
- Trial name
- NCT04127396
- Testing
- Lenvatinib Pill, Transarterial chemoembolization(TACE), Sorafenib
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Ditan Hospital
Carcinoma, Hepatocellular
SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
This is a pilot study where patients with Hepatocellular Carcinoma (HCC) that have failed Transarterial Chemoembolization (TACE) will be treated with Stereotactic Body Radiation Therapy (SBRT).
- Trial name
- NCT02221778
- Testing
- SBRT
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- University of Sao Paulo
Primary Hepatocellular Carcinoma
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
The subjects of primary hepatocellular carcinoma diagnosed pathologically or clinically will be grouped according to the size, location, number and function of the liver, and respectively received Intensity-modulated Radiation…
- Trial name
- NCT03614546
- Testing
- SBRT, IMRT, Hepatectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Xiangya Hospital of Central South University